Stockreport

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology As...

Editas Medicine, Inc.  (EDIT) 
Last editas medicine, inc. earnings: 2/26 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.editasmedicine.com
PDF All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni- [Read more]